CAMG
CPRX

CWA Asset Management Group’s Catalyst Pharmaceutical CPRX Stock Holding History

CWA Asset Management Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-52,129
Closed -$1.03M – 665
2025
Q3 		$1.03M Buy
52,129
+5,644
+12% +$116K 0.04% 347
2025
Q2 		$1.01M Buy
46,485
+2,404
+5% +$56.7K 0.04% 323
2025
Q1 		$1.07M Buy
44,081
+10,383
+31% +$234K 0.05% 291
2024
Q4 		$703K Buy
33,698
+6,853
+26% +$147K 0.04% 328
2024
Q3 		$534K Buy
+26,845
New +$498K 0.03% 349

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CWA Asset Management Group's CPRX Position: Q4 2025 in Review

CWA Asset Management Group sold out of Catalyst Pharmaceutical (CPRX) in Q4 2025, closing a stake of 52,129 shares — an estimated $1.03M sold.

CWA Asset Management Group first reported a position in CPRX in Q3 2024 and held it in 5 quarters. The position peaked at $1.07M in Q1 2025. 373 funds tracked by Wall St. Rank hold CPRX as of Q4 2025.

  • CWA Asset Management Group reported no remaining Catalyst Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • CWA Asset Management Group sold 52,129 Catalyst Pharmaceutical shares in Q4 2025, an estimated $1.03M.
  • CWA Asset Management Group first reported a position in Catalyst Pharmaceutical in Q3 2024 and held it in 5 quarters.
  • CWA Asset Management Group's Catalyst Pharmaceutical position peaked at $1.07M in Q1 2025.
  • 373 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2025.

Based on CWA Asset Management Group's 13F filing for Q4 2025, filed 7 Jan 2026.